Global Denosumab Market, By Drug Classification (Prolia, Xgeva, and Others), End-Users (Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical Centres, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) – Industry Trends and Forecast to 2030.
Denosumab Market Analysis and Size
The incidence of osteoporosis tends to increase with age, particularly in postmenopausal women, due to hormonal changes that occur during menopause. However, osteoporosis can also affect men and younger individuals. According to the International Osteoporosis Foundation (IOF), worldwide, an estimated 200 million women have osteoporosis. Additionally, approximately 1 in 3 women over the age of 50 and 1 in 5 men over the age of 50 will experience osteoporotic fractures in their lifetime.
Data Bridge Market Research analyses that the global denosumab market which was USD 2,892.17 million in 2022, would rocket up to USD 7,109.92 million by 2030, and is expected to undergo a CAGR of 11.9% during the forecast period. This indicates the market value. “Prolia” dominates the drug classification segment of the global denosumab market owing to the growing demand for better treatment for bone related disorders.
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drug Classification (Prolia, Xgeva, and Others), End-users (Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical Centres, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina and Rest of South America
|
|
Market Players Covered
|
Merck & Co., Inc (U.S.), Amneal Pharmaceutical Inc (U.S.), Teva Pharmaceutical Industries Ltd (Israel), Zydus Cadila (India), Novartis Ag (Switzerland), Pfizer Inc (U.S.), Astrazeneca (U.K.), Glaxosmithkline Plc (U.K.), Bristol Myers Squibb Company (U.S.), Johnson & Johnson Service Inc (U.S.), F. Hoffmann- La Roche Ltd (Switzerland), Bayer AG (Germany), Amgen Inc (U.S.), Sanofi (France), Biogen (U.S.), Regeneron Pharmaceuticals Inc (U.S.), Eli Lilly the Company (U.S.), AbbiVie Inc (U.S.), Mylan N.V. (U.S.), and Eisai Co., Ltd (Japan)
|
|
Market Opportunities
|
|
Market Definition
Denosumab injection (Prolia) refers to the type of drug that is utilized for treating osteoporosis, which is a condition in which the bones become thin and weak and breaks easily among the women population. The condition occurs mainly in women who have undergone menopause and have an increased risk for fractures.
Global Denosumab Market Dynamics
Drivers
- Increasing Prevalence of Osteoporosis
Osteoporosis is a common condition characterized by decreased bone density and increased risk of fractures. As the global population ages, the prevalence of osteoporosis is expected to rise, driving the demand for medications like Denosumab that can help prevent fractures and improve bone health.
- Growing Awareness and Diagnosis
With increased awareness about osteoporosis and its impact on overall health, more individuals are seeking diagnosis and treatment. This increased awareness and diagnosis contribute to the demand for medications like Denosumab.
- Efficacy and Safety Profile for Expanded Indications
Denosumab has demonstrated efficacy in reducing the risk of fractures and improving bone density in clinical trials. Its safety profile, when used as directed, has been generally well-tolerated. These factors contribute to its popularity and adoption in the market. Denosumab has received approvals for additional indications beyond osteoporosis, such as the prevention of skeletal-related events in patients with bone metastases from solid tumors and the treatment of giant cell tumors of bone. These expanded indications have widened the market for Denosumab.
Opportunities
- Research and Development Proficiencies
Ongoing research and development efforts in the field of bone health provide opportunities for the development of new therapies and combination treatments. Denosumab manufacturers can explore these opportunities to further optimize the efficacy and safety of Denosumab or develop novel treatments that complement its mechanism of action.
- Increasing Aging Population
The global population is aging, with a larger proportion of elderly individuals. As age is a significant risk factor for osteoporosis and other bone-related conditions, this demographic trend presents a substantial opportunity for the Denosumab market to cater to the growing demand for bone health treatments.
Restraints/Challenges
- Competition from Existing Therapies
Denosumab faces competition from other established therapies for osteoporosis treatment, such as bisphosphonates and selective estrogen receptor modulators. These therapies have been widely used and have a long history of efficacy and safety, making it challenging for Denosumab to gain market share.
- High Cost of Denosumab Therapy and Treatment
Denosumab is a biologic therapy, and biologics often come with a higher cost compared to traditional small molecule drugs. The high cost of Denosumab may limit its accessibility and affordability for some patients, especially in regions with limited healthcare resources or inadequate insurance coverage.
- Long-term Safety and Efficacy Data
While Denosumab has demonstrated efficacy and safety in clinical trials, long-term data on its use beyond several years is limited. The availability of long-term safety and efficacy data is crucial to gain the confidence of healthcare providers and patients, especially for chronic conditions like osteoporosis.
- Complex Reimbursement Challenges
Reimbursement policies and pricing negotiations with healthcare systems and insurance providers can pose challenges for Denosumab manufacturers. The availability of reimbursement and formulary coverage may vary across different regions, impacting patient access and market penetration.
This global denosumab market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Denosumab market contact Data Bridge Market Research for an analyst brief, our team will help you make an informed market decision to achieve market growth.
Recent Developments
- In February 2023, Sandoz announced that the biologics license application (BLA) for its denosumab biosimilar candidate for review had been accepted by the Food and Drug Administration (FDA) for the treatment of premenopausal patients with osteoporosis who are at increased risk of fractures
- In November 2022, Luye Pharma Group’s subsidiary Boan Biotech announced that their Denosumab Injection (Boyoubei) got approval for the product launch in China by the National Medical Products Administration (NMPA) for the treatment of postmenopausal women with osteoporosis at high risk of fractures.
Global Denosumab Market Scope
The global denosumab market is segmented on the basis of drug classification, end-users, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug Classification
- Prolia
- Xgeva
- Others
End-Users
- Hospitals
- Homecare
- Specialty Clinics
- Ambulatory Surgical Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Global Denosumab Market Regional Analysis/Insights
The global denosumab market is analysed, and market size insights and trends are provided by country, drug classification, end-users, and distribution channel as referenced above.
The countries covered in the global denosumab market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina and Rest of South America.
North America is expected to dominate the global denosumab market because of the strong base of healthcare facilities, the strong presence of major players in the market, the extraordinary healthcare infrastructure, and the large pool of people having bone disorders, mostly women.
Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote healthcare, the rising health awareness among the people, and the growing demand for advanced medical technology for diagnosis and treatment, the large population pool, and the growing demand for quality healthcare in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends, and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The global denosumab market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the global denosumab market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the global denosumab market. The forecast period is 2015-2020.
Competitive Landscape and Global Denosumab Market Share Analysis
The global denosumab market competitive landscape provides details by competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, application dominance. The above data points provided are only related to the companies' focus related to the global denosumab market.
Some of the major players operating in the global denosumab market are:
- Merck & Co., Inc (U.S.)
- Amneal Pharmaceutical Inc (U.S.)
- Teva Pharmaceutical Industries Ltd (Israel)
- Zydus Cadila (India)
- Novartis Ag (Switzerland)
- Pfizer Inc (U.S.)
- Astrazeneca (U.K.)
- Glaxosmithkline Plc (U.K.)
- Bristol Myers Squibb Company (U.S.)
- Johnson & Johnson Service Inc (U.S.)
- F. Hoffmann- La Roche Ltd (Switzerland)
- Bayer AG (Germany)
- Amgen Inc (U.S.)
- Sanofi (France)
- Biogen (U.S.)
- Regeneron Pharmaceuticals Inc (U.S.)
- Eli Lilly the Company (U.S.)
- AbbiVie Inc (U.S.)
- Mylan N.V. (U.S.)
- Eisai Co., Ltd (Japan)
SKU-